Home Business

Natco Pharma FY09 net rises 8.5% at Rs 44 cr

Hyderabad-based drug maker Natco Pharma reported an 8.5 per cent rise in its consolidated net profit at Rs 43.98 crore for the year ended March 2009, compared with Rs 40.52 crore posted in the previous year. - Lupin buys worldwide rights for nasal spray AllerNaze - Glenmark"s diabetes drug to enter phase lll trials - Emami realty arm to be listed on BSE in 3-4 months - Piramal Healthcare gets nod for appt of Nandini Piramal as ED - Sun Pharma gets USFDA nod for anti hypertensive drug - Step up vigil to stop fake Made-in-India drugs in Africa: govt Revenues were up to Rs 465 crore from Rs 364 crore in the same period, registering a growth of 28 per cent. The company stated that the growth in profit was lower on account of expenses on Phase I clinical trials of its new chemical entity with multiple oncological indications.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
BSE pitches its new F&O contract for Budget play
The Union Budget is a few weeks away and entities across sectors are busy drafting their wishlists. Officials of the Bombay Stock Exchange (BSE), Asia’s oldest, are busy, too, but to get the exchange’s almost dormant equity derivatives segment in order by the Budget eve.
Popular Articles
quick payday loans

Upto Centre to resolve Telangana issue: TRS chief
TRS supremo K Chandrasekhar Rao today threw the ball in Centre"s court on the creation of a separate Telangana state and insisted that Hyderabad will be the capital of the proposed state.

Use the company car, decline its leased flat, advise experts
New tax rules on perks need some smart changes in what you claim.

© Copyright 2009